MacroGenics investigates three patient deaths in Phase 2 prostate cancer drug trial
10 May 2024
Clinical ResultPhase 2ADC
MacroGenics reported on Thursday afternoon that three patients died in a mid-stage trial of its antibody-drug conjugate for prostate cancer. Two participants died due to pneumonitis and the third died from a pleural effusion.
The biotech’s shares $MGNX plummeted 66% to $4.91 premarket on Friday.
A total of five patients died in the trial, although two of the deaths were deemed unrelated to vobramitamab duocarmazine, also dubbed vobra duo. All but one patient in the trial had a treatment-emergent adverse event and 33.5% experienced a grade 3 or higher event.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.